|Bid||66.01 x 800|
|Ask||66.80 x 1200|
|Day's Range||61.27 - 66.87|
|52 Week Range||12.52 - 105.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.03|
Both of these biotechs have promising COVID-19 programs. But one of them appears to have a clear edge.
Johnson & Johnson’s investigational COVID-19 vaccine entered Phase 3 clinical trials this week, making it the fourth vaccine candidate in the U.S. to do so and providing additional details that can help investors differentiate the pool of late-stage coronavirus vaccines.
The company said it will start a 10,000-person trial of its vaccine among volunteers in the U.K. A larger, 30,000-person trial in the U.S. could start in October.